Table 4. Odds of treatment reaction and death in snakebite patients treated with different antivenoms at Abdurafi field hospital between 2015 and 2019.
| Antivenom | n | Outcome (%) | Odds ratio (95% CI) | p-value | Adjusted odds ratio** (95% CI) | p-value |
|---|---|---|---|---|---|---|
| Treatment reaction | ||||||
| Fav-Afrique | 148* | 2 (1.4%) | 1.00 (reference) | |||
| VacSera | 164 | 30 (18.3%) | 16.3 (3.83–69.7) | <0.001 | 16.2 (3.79–69.2) | <0.001 |
| EchiTAb-PLUS-ICP | 156 | 11 (7.1%) | 5.54 (1.21–25.4) | 0.028 | 5.78 (1.25–26.7) | 0.024 |
| Death | ||||||
| Fav-Afrique | 148* | 2 (1.4%) | 1.00 (reference) | |||
| VacSera | 164 | 8 (4.9%) | 3.77 (0.79–18.0) | 0.097 | 4.56 (0.90–23.0) | 0.066 |
| EchiTAb-PLUS-ICP | 156 | 3 (1.9%) | 1.44 (0.24–8.75) | 0.691 | 1.16 (0.18–7.34) | 0.871 |
* excluding one patient who defaulted treatment (discharged against medical advice)
** adjusted for age, sex, and time from bite until admission